Cariprazine for acute and maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy
Leslie Citrome Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY, USA Abstract: Cariprazine is an oral antipsychotic approved in the US and EU for the treatment of schizophrenia. Cariprazine differs from other antipsychotics in that it is a dopamine D3- and D...
Saved in:
Main Author: | Citrome L |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2018
|
Subjects: | |
Online Access: | https://doaj.org/article/6776b85ca77941779d2f21b58ef17f49 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies
by: Barabássy Á, et al.
Published: (2021) -
Cariprazine: Patients with Treatment-Resistant Schizophrenia
by: Aubel T
Published: (2021) -
Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies [Corrigendum]
by: Barabássy Á, et al.
Published: (2021) -
Case Report: Cariprazine Efficacy in Young Patients Diagnosed With Schizophrenia With Predominantly Negative Symptoms
by: Octavian Vasiliu
Published: (2021) -
Cariprazine in Three Acute Patients with Schizophrenia: A Real-World Experience
by: Montes JM, et al.
Published: (2021)